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Abstract: Oligonucleotide gold nanoparticle conjugates are being used as diagnostic tools 
and gene silencing experiments. Thiol-chemistry is mostly used to functionalize gold 
nanoparticles with oligonucleotides and to incorporate DNA or RNA molecules onto gold 
surfaces. However, the stability of such nucleic acid–gold nanoparticle conjugates in certain 
conditions may be a limitation due to premature break of the thiol-gold bonds followed by 
aggregation processes. Here, we describe a straightforward synthesis of oligonucleotides 
carrying thioctic acid moiety based on the use of several thioctic acid-L-threoninol derivatives 
containing different spacers, including triglycine, short polyethyleneglycol, or aliphatic 
spacers. The novel thioctic-oligonucleotides were used for the functionalization of gold 
nanoparticles and the surface coverage and stability of the resulting thioctic-oligonucleotide 
gold nanoparticles were assessed. In all cases gold nanoparticles functionalized with 
thioctic-oligonucleotides had higher loadings and higher stability in the presence of thiols 
than gold nanoparticles prepared with commercially available thiol-oligonucleotides. 
Furthermore, the thioctic derivative carrying the triglycine linker is sensitive to cathepsin B 
present in endosomes. In this way this derivative may be interesting for the cellular 
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delivery of therapeutic oligonucleotides as these results provides the basis for a potential 
endosomal escape. 
Keywords: thioctic acid; threoninol; DNA; DNA-gold nanoparticle conjugates; stability; 
surface coverage; cathepsin 
 
1. Introduction 
During the past decade colloidal gold nanoparticles (AuNPs) have become attractive materials due 
to an increasing interest in their potential applications in biotechnology, molecular diagnostics and 
biomedicine [1–6]. Because of their unique properties such as size and shape-dependent optical and 
electronic features, good biocompatibility and the ability to bind ligands containing thiols, phosphines 
and amines, they have emerged as useful tools for the design of biosensors [3], the development of 
methods for cancer detection [7,8] and potential vehicles for drug delivery [9]. The use of AuNPs 
requires an appropriate colloidal stability. The immobilization of organic molecules or biomolecules 
onto AuNps surface significantly promotes their dispersion in aqueous solutions and improves the 
stability of the colloidal suspensions [10]. 
There are numerous examples of biomolecules that have been immobilized onto AuNPs such as 
peptides [11], proteins [12,13] or nucleic acids [14]. Specifically, there are many examples reported in 
the literature on the use of nucleic acid-functionalized gold nanoparticles. For instance, they have been 
applied as a scaffold to construct higher ordered materials [15] or in the field of biodiagnostics [6,15] 
and bioimaging [16] and as well used for therapeutic applications such as a potent cell transfection and 
gene regulation material [6]. 
The conjugation of AuNps with biomolecules such as oligonucleotides, proteins and antibodies can 
be carried out through chemisorption of the biomolecule to the particle surface or electrostatic 
interactions between the biomolecule. The use of heterobifunctional ligands allows the functionalization 
of AuNps with biomolecules through covalent attachments, or specific biomacromolecular interactions 
such as streptavidin/biotin [17–20]. 
Due to the strong affinity of thiolated species for gold surfaces and the ease of modification of 
nucleic acids with thiolated derivatives, thiolated oligonucleotides have been extensively used in the 
preparation of DNA-functionalized AuNps since the pioneering publication of Mirkin and co-workers 
in 1996 [21]. 
Although such oligonucleotide-AuNP conjugates have been demonstrated to be very stable under 
most DNA detection conditions, limited stability has been observed in certain biological media due to 
a partial desorption of thiolated oligonucleotides by ligand exchange in the presence of some additives 
(e.g., dithiothreitol (DTT), mercaptoethanol or biogenic thiols) [22–24]. 
Many efforts have been carried out in order to increase the colloidal stability by designing surface 
ligands that keep AuNPs from aggregating. For instance, Taton et al. functionalized AuNPs with 
thiolated systems like poly(L-lysine)-graft-poly(ethyleneglycol (PLL-g-PEG graft copolymers).  
The conjugates were stable under extreme conditions, making this polymer a promising ligand to use 
in biotechnological applications [24]. There are also several examples reported in the literature to 
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enhance the stability in systems containing oligonucleotide-AuNP conjugates. Mirkin et al. described a 
few years ago the use of modified steroid cyclic disulfide or a novel trithiol-capped oligonucleotide 
that exhibited higher stabilities than the conventional acyclic monothiol-capped oligonucleotide-AuNp 
conjugates toward DTT treatment. These stable conjugates were studied as useful tools for diagnostic 
probes in colorimetric assays and detection methods [21]. 
Thioctic acid (TA) has been extensively used for the functionalization of gold surfaces [18].  
In most cases, TA has been conjugated with polyethyleneglycol (PEG) units giving decorated  
TA-appended-polyethyleneglycol functionalized AuNPs, thereby showing better stabilities than their 
acyclic disulfide and single thiol counterparts [18, 25-27]. The conjugation of oligonucleotides with 
TA has been recently reported by Graham and co-workers using two different methodologies [28,29]. 
These include: (I) the use of a TA H-phosphonate derivative to introduce the resultant disulfide unit at 
5'-termini of oligonucleotides [28] and (II) the use of the N-hydroxy-succimidyl ester of TA to 
incorporate the TA molecule in a solid support having an amino-linker followed by the assembly of the 
oligonucleotide by the stepwise approach [29].  
Another important factor to consider AuNPs as promising vehicles for drug delivery, apart from 
their systemic stability, is the selective cargo release at the target tissue [30,31]. In these terms, the 
conjugation of oligonucleotides with TA derivatives could facilitate the incorporation of spacers with 
potential breaking points that would allow oligonucleotides to be released at the cellular target site.  
It is known that several classes of proteinases are overexpressed by many tumor cells, including cathepsins. 
In particular, cathepsin B plays a critical role in tumor progression [32]. In addition, several works has 
reported that polypeptides linker has been used for the endosomal escape of several drugs [33–36] because 
of the lability to cathepsin. Thus, we thought the possibility to consider the incorporation of linkers 
susceptible to cathepsin B in our oligonucleotide-TA conjugates in order to release the therapeutic 
oligonucleotide by the action of this protease. 
In this work, we investigate the effect of introducing several spacers between the oligonucleotide 
and the TA moiety (Figure 1). It has been reported that the introduction of spacers between the AuNPs 
surface and biomolecules not only leads to an increased immobilization efficiency [37,38], but also to 
functional immobilized biomolecules [38,39]. Moreover, spacers have been employed to protect the 
gold surface from thiolated compounds by providing a dense and ordered coating layer [27,40–42]. 
Then, the contribution of a spacer, in addition of moving the recognition tracts of oligonucleotides 
from the particle surface, may be crucial to the stability of the resulting AuNP conjugates. 
Here, L-threoninol was selected as a building block to incorporate the TA residue tethered with 
different spacers into DNA (Figure 1). We synthesized the thioctic-DNA analogue (TA_I) without any 
spacer, which was used as a reference and four different thioctic-DNA analogues containing a spacer. 
In particular, TA_II conjugate containing an ethylene glycol-like (hexaethylene glycol) unit between 
the oligonucleotide and the threoninol moiety was obtained via phosphate linkages. Finally, the 
TA_III series containing an oligo(ethylene glycol)-like molecule, a triglycine peptide and an alkyl 
group as spacers. These three spacers were introduced via amide groups in order to separate the 
threoninol unit from the TA residue. The resulting oligonucleotides were then successfully loaded onto 
AuNPs. The ability of these TA-terminated oligonucleotides to improve the stability of the 
corresponding DNA-AuNP conjugates in aqueous solution in the presence of DTT was investigated. 
For comparison purposes, the same experiments were performed with AuNP conjugates prepared with 
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oligonucleotides modified with commercially available thiol- and acyclic disulfide-oligonucleotides. 
Consequently, this synthetic strategy may be useful to prepare TA-terminated oligonucleotides 
modified at the 3'-end by the incorporation of several spacers with different size and properties. To the 
best of our knowledge, the use of this strategy in synthesizing such modified oligonucleotides to 
functionalize AuNPs has not been reported yet. In addition, the effect promoted by some proteases like 
Cathepsin B on our TA-terminated oligonucleotides was evaluated. These preliminary results could 
offer a strategy in the search of new drug delivery vehicles containing oligonucleotides. 
Figure 1. Preparation of gold nanoparticles functionalized with TA-terminated oligonucleotides. 
 
2. Results and Discussion  
2.1. Synthesis of Solid Supports Functionalized with TA Derivatives  
In order to connect TA to the oligonucleotides we used the readily available aminodiol L-threoninol 
(Figure 1). The amino group of L-threoninol allows the selective addition of the TA leaving the 
primary and secondary alcohol functions for the preparation of DMT building blocks needed for 
oligonucleotide synthesis. L-Threoninol has been extensively used to introduce all kinds of interesting 
molecules containing a carboxylic acid function into oligonucleotides [43] including a thiol group 
protected with the S-tert-butylsulfanyl group [44]. It was envisaged that the threoninol unit would 
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allow us to directly connect the TA molecule with the oligonucleotide chain (TA_I, Figure 1) or after a 
commercially available hexaethylene glycol spacer (TA_II, Figure 1). In addition, the threoninol 
linker will allow the introduction of several spacers between the threoninol molecule and the 
oligonucleotide. We selected the following molecules as spacers: (i) an oligo(ethylene glycol) 
molecule (TA_III(a), Figure 1); (ii) a short peptide (triglycine, TA_III(b), Figure 1) and (iii) an 
aliphatic chain (TA_III(c), Figure 1). 
The preparation of the appropriate solid supports carrying the TA derivatives was undertaken in 
order to obtain 3'-TA oligonucleotides (TA_I, TA_II and TA_III respectively). First, the TA 
threoninol derivative (compound 1, Scheme 1) was prepared. L-threoninol was reacted with TA via 
amide bond formation by activating the carboxylic acid with HOBt and EDCI. Next, the primary 
alcohol was protected with the 4,4'-dimethoxytrityl (DMT) group to give the compound 2 and 
subsequently, reacting the secondary alcohol with succinic anhydride yielded the derivative 3.  
This compound was used to functionalize the amino-controlled pore glass support (long chain amino 
alkyl-controlled pore glass, LCAA-CPG) to yield the CPG solid support 4. This solid support was used 
to prepare oligonucleotides labeled as TA_I (see below) and TA_II with the hexaethylene glycol 
spacer using the commercially available phosphoramidite (Figure 1). 
Scheme 1. Synthesis of solid support 4 and phosphoramidite 12 used for the preparation of 
3'-and 5'-TA oligonucleotides TA_I, TA_II and 5'TA_I, respectively.  
 
Reagents and conditions: (i) Thioctic acid, EDCI, HOBt, DIEA, DMF; (ii) dimethoxytrityl chloride, pyr;  
(iii) succinic anhydride, DMAP, pyr; LCAA CPG (long chain aminoalkyl controlled pore glass), TBTU, 
TEA, ACN; (v) 2-cyanoethyl-N,N-diisopropylaminohlorophosphine, DIEA, DCM.  
Next, three different TA-terminated oligonucleotides (TA_III(a), TA_III(b) and TA_III(c)), 
containing different spacers such as an oligo(ethylene glycol)-like molecule, a triglycine peptide and 
an alkyl group respectively were prepared. The synthesis of the solid supports 11a-11c required for the 
preparation of the corresponding DNA analogues is depicted in Scheme 2. The corresponding 
carboxylic acids N-Boc-N'-succinyl-4,7,10-trioxa-1,13-tridecanediamine, Boc-Gly-Gly-Gly-OH and 
N-Boc-8-aminooctanoic acid were first transformed into their 4-nitrophenyl esters (5a–5c) and 
subsequently reacted with L-threoninol to obtain the corresponding N-Boc-compounds 7a, 7b and 7c in 
good yield (69%, 78% and 96%, respectively). Then, the Boc group was removed under acidic 
conditions yielding the corresponding amines as trifluoroacetate salts, which were used in the next step 
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without further purification. Next, the reaction of the resulting free amines analogues with TA,  
using the same “active-ester” methodology described before but this time using the 4-nitrophenyl ester 
6 yielded compounds 8a, 8b and 8c. Finally, the primary alcohol was protected with a DMT group and 
the corresponding 3'-hemisuccinate derivatives were synthesized to prepare the corresponding 
functionalized solid supports 11a–11c as described above. 
Scheme 2. Synthesis of the solid supports needed for the preparation of 3'-TA- terminated 
oligonucleotides TA_III(a), TA_III(b) and TA_III(c).  
 
Reagents and conditions: (i) Carboxylic acids III(a)-III(c) or thioctic acid, DCC, p-nitrophenol, pyr.;  
(ii) 5a–5c, DMF; (iii) TFA 10% DCM; (iv) 6, DMF. (v) dimethoxytrityl chloride, pyr.; (vi) succinic 
anhydride, DMAP, pyr.; (vii) LCAA CPG (long chain aminoalkyl controlled pore glass), TBTU, TEA, ACN. 
Furthermore, as a proof of concept about the versatility of the present study, we also derivatized the 
DMT-protected alcohol 2 to synthesize the corresponding phosphoramidite 12 (Scheme 1), which was 
obtained in good yield (77%) after purification by flash chromatography. 
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synthesis crudes are depicted in Figure 2A,B. HPLC profiles of the rest of the samples are shown in 
the SI (Figure S1). We observed that treatments (i) and (ii) lead to similar HPLC profiles in all cases 
and the amount of side compound was increased with the prolonged treatment with ammonia at 55 °C 
(treatment iii). We observed a small increase of side compounds (14% to 17%) in the case of 
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(T12)TA_I, however, with the other oligonucleotides we detected higher increases of side compounds 
(25% to 41% for (T12)TA_III(a), 33% to 51% for (T12)TA_III(b) and 24% to 36% for 
(T12)TA_III(c)) (Supplementary Information, Table S2). In each case, the main peaks were collected 
and analyzed by mass spectrometry (Supplementary Information, Table S1). The peak with the highest 
retention time (tR) corresponded with the TA-terminated oligonucleotide. In all cases we observed a 
compound eluting at tR = 3.2 min. According to the mass analysis this compound was the result of a β-
elimination process for samples (T12)TA_I, (T12)TA_III(a) and (T12)TA_III(c) (Figure S1, SI). In 
contrast, for (T12)TA_III(b) this same side compound resulted from the amide bond-cleavage. In addition 
to the hydrolysis products we also observed small amounts of side products eluting between tR = 3.2 min 
and the main peak. Mass spectrometry analyses of these side compounds (Supplementary Information, 
Table S1) indicate that they may correspond to different oxidation products of the disulfide group. 
Figure 2. HPLC profiles of model oligonucleotides (XBridge OST C18 column).  
(A) (T12)TA_I and (B) (T12)TA_III(a) after different treatments with aqueous concentrated 
ammonia. Example of HPLC profiles of purified oligonucleotides; (C) TA_III(a) and  
(D) TA_III(c). ▼ stands for TA-terminated oligonucleotides and ■ stands for a β-elimination 
side product.  
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ammonia. The DNA analogues TA_I, TA_II and TA_III(a)–(c) (5'CGG AGG TAC ATT CGA CTT 
GAT-X3', X stands for 3'-modifications containing the TA residue) (Figure 1) were prepared using the 
appropriate solid supports (Schemes 1 and 2). Finally, compound 12 incorporated into the same 
sequence at the 5'-end. The coupling efficiency was >90% proving the efficiency of these 
phosphoramidite (Supplementary Information, Table S3). 
After HPLC analysis, all modified oligonucleotides presented a major peak with some impurities, 
that were around 12%–14% for TA_I and TA_II and 25%–31% for TA_III(a)–(c). The main products 
were analyzed by mass spectrometry giving the expected mass (Supplementary Information,  
Table S3). For the AuNPs surface coverage studies of AuNPs a fluorescein was introduced at the 5'-
termini of the same sequence obtaining the corresponding fluorescently labeled oligonucleotides 
(F)TA_I, (F)TA_II and (F)TA_III(a)–(c). All products were purified by HPLC obtaining the desired 
oligonucleotide as main product (Supplementary Information, Table S3). 
We also prepared two additional 3'-thiolated DNA derivatives ALK_DS and ALK_SH, (5'-CGG 
AGG TAC ATT CGA CTT GA-Y-3', being Y 3'-linear alkyldisulfide or alkylthiol modifications), 
which were used as controls and their corresponding fluorescently labeled versions (F)ALK_DS and 
(F)ALK_SH. A commercially available solid support, containing the linear alkyldisulfide 
modification (3'-Thiol modifier C3 S-S CPG; Link Technologies) was used to prepare the 
oligonucleotide carrying an acyclic disulfide unit at 3'-termini (ALK_DS). The fluorescent dye was 
attached at the 5'-end following the procedure described previously to obtain (F)ALK_DS. After HPLC 
analysis, we observed in both cases a single peak that had the expected mass (Supplementary 
Information, Table S3). Both oligonucleotides were desalted and used in the next step without further 
purification. The alkylthiol oligonucleotides ALK_SH and (F)ALK_SH were obtained from the 
corresponding alkyldisulfide oligonucleotides by reduction of the disulfide moiety to thiol in the 
presence of TCEP·HCl following a procedure described in the literature [44,45]. 
2.3. Surface Coverage Quantification and Stability Tests of Oligonucleotide-Gold Nanoparticle Conjugates  
In order to study the effect caused by the previously synthesized TA-terminated oligonucleotides on 
the coverage and stability of gold nanoparticles, all modified oligonucleotides at their 3'-termini along 
with their fluorescent labeled versions were loaded onto colloidal gold nanoparticles (9.7 nm) by a 
slow increase of the NaCl concentration and sonication after each saline incremental addition to reach 
a total salt concentration of 0.15 M (10 mM phosphate, pH 7.04, 0.15 M NaCl, 0.01% NaN3) [37,46]. 
Previously the use of higher salt concentrations (0.3 M NaCl) was described [28,29]. In our hands 
these protocols are fine with regular alkylthiol group but are not suitable for oligonucleotides carrying 
lipoic acid moieties as the resulting nanoparticles have a strong tendency to aggregate. Then the 
number of oligonucleotides loaded on each AuNp was calculated by displacement with a 1 M DTT 
solution of the corresponding fluorescently labeled oligonucleotides [29,47,48]. By measuring the 
concentration of oligonucleotides and gold nanoparticle conjugates of each sample, an average number 
of oligonucleotides per particle was calculated. Then, the average area occupied by an oligonucleotide 
(footprint) was calculated by dividing the calculated surface area (nm2) by the average number of 
oligonucleotides per particle. Results are summarized in Table 1. 
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Table 1. Surface coverage and half-lives data for oligonucleotide-gold nanoparticle conjugates. 
Conjugate Strands/Particle Footprint (nm2) t1/2 (min) 
AuNP-TA_I 94 ± 7 3.2 ± 0.2 344 ± 12 
AuNP-TA_II 93 ± 13 3.2 ± 0.4 282 ± 11 
AuNP-TA_III(a) 141 ± 10 2.1 ± 0.3 444 ± 8 
AuNP-TA_III(b) 103 ± 13 2.9 ± 0.4 354 ± 10 
AuNP-TA_III(c) 102 ± 12 2.8 ± 0.3 450 ± 15 
AuNP-ALK_DS 40 ± 2 7.4 ± 0.1 4 ± 1 
AuNP_ALK_SH 97 ± 7 3.0 ± 0.2 12 ± 2 
We found similar surface coverage results with AuNP-TA_I without any spacer (94 strands/particle) 
and our control ALK_SH (97 strands/particle). However, the functionalization was less efficient for 
AuNP-ALK_DS (40 strands/particle). A possible explanation of this result could be the larger 
anchoring group present in ALK_DS oligonucleotide compared to ALK_SH. Then, the ability of the 
dialkyldisulfide group to form dense layers would be lower than the alkylthiol group. In addition, it is 
described that the adsorption of a dialkyldisulfide is possible, but thermodinamically not stable [49]. 
The process implies the cleavage of the disulfide bond, which generates two monoalkylthiolated 
branches, that do not adsorb adjacent to each other [50]. Maybe the monolayer obtained in this case is 
not so uniform compared with the monolayer formed with ALK_SH oligonucleotide in terms of 
thiolated species adsorbed onto the surface explaining the reduction in the coverage efficiency. 
We observed different trends depending on the linker nature and how it has been incorporated. 
AuNP-TA_I and AuNP-TA_II showed similar surface coverage results. In this case, the introduction 
of a hexaethylene glycol spacer did not lead to a higher coverage. Maybe, the threoninol and the 
phosphate groups, which are placed very close to the surface, are preventing to achieve a higher 
loading due to steric and electrostatic effects. In the case of the TA_III series, a slight increase in the 
ligand density was observed when a spacer similar in length (alkyl or a triglycine peptide) was 
introduced. A higher density of ligand was observed when an oligo(ethylene glycol) was introduced 
between the TA group and the oligonucleotide (141 strands/particle), that is an increase of around 50% 
on DNA loading compared with AuNP-TA_I conjugates. This result indicates the beneficial effect of 
the spacer and is in good agreement with other results published in the literature [37], where thiolated 
oligonucleotides with and without an oligo(ethylene glycol) spacer were used to functionalize AuNP. 
The authors reasoned that the spacer moves the DNA tract away from the gold surface thus reducing 
the interstrand repulsion between negatively charged phosphate/sugar backbones and as well the 
tendency of DNA nucleobases to interact with the gold surface. An important characteristic to take into 
account regarding monolayers formed on the surface of AuNPs is the radius of curvature.  
A consequence of this curvature is a decrease in the chain density moving away from the surface of the 
core. The decreasing density translates into an enhanced mobility of the terminal tracts of a ligand 
chain [51]. For the TA-terminated DNA oligonucleotides the decreasing density seems to minimize the 
interstrand repulsions of the negatively charged tract. It could be a plausible explanation for the higher 
density of packing obtained with all three AuNp-TA_III conjugates.  
Next, we studied the stability of our AuNP-conjugates against ligand exchange in the presence of 
DTT. At high concentration, DTT can displace thiolated ligands, resulting in progressive aggregation 
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of the AuNPs. Then, the ability of the spacers to provide additional shielding of the inorganic core was 
evaluated by assessing the aggregate formation in the presence of DTT (100 mM) at 40 °C. Figure 3A 
shows the UV-Vis spectra taken at different times for AuNP-TA_I. During time evolution of the UV-Vis 
spectra, a decay of the plasmon peak of colloidal gold (522 nm) was observed, while the intensity 
between 600 and 700 nm increased. Then, the displacement of oligonucleotides from AuNPs was 
monitored by measuring the changes in signal intensity at 675 nm with time (Figure 3B). The time required 
to reach half of the maximum intensity (t1/2) was used to compare the stability of each AuNP-conjugate. 
Table 1 summarizes the results obtained in each case. Comparing the conjugates formed with the TA series 
with the conjugates formed with oligonucleotides containing an alkylthiol or an acyclic alkyldisulfide a 
great difference in the stability was observed. The complete aggregation occurred at 15 min and 30 min for 
AuNp-ALK_DS and AuNp_ALK_SH respectively. This is in good agreement with other results 
published in the literature [22,29,52], where oligonucleotides were modified with cyclic disulfides to 
functionalize AuNPs. In these cases a large increase in the stability was observed in comparison with 
AuNPs functionalized with monoalkylthiol- or acyclic disulfide-oligonucleotides, suggesting that those 
differences might be due to different binding affinities of the different thiolated groups to gold surfaces.  
Figure 3. (A) Time evolution of UV-Vis spectra of AuNp-TA_I in 100 mM DTT;  
(B) Displacement of modified TA-appended oligonucleotides from AuNPs by measuring the 
changes in signal intensity at 675 nm with time upon treatment with a 100 mM DTT solution.  
 
Focusing on the results obtained with conjugates formed with TA-terminated oligonucleotides, we 
found that conjugate formed with TA_I (without a spacer) showed a high stabilization in the presence 
of DTT (t1/2 344 min.). The conjugates formed with TA_III(a) and TA_III(c), (containing an 
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oligo(ethylene glycol)-like molecule and an alkyl group as spacer respectively) were very similar and 
showed a clear increase of about 100 min in t1/2 compared with conjugates formed with TA_I. On the 
other hand, when the spacer was a triglycine peptide (TA_III(b)), the t1/2 value obtained was very 
similar to conjugates formed with TA_I. Finally, the conjugates formed with TA_II containing 
hexaethylene glycol as a spacer) showed a clear decrease (62 min) in t1/2 when compared with TA_I. 
The replacement rate of thiolated ligands depends on a number of parameters such as the packing 
density, the order degree or the intermolecular interactions between the ligands [53]. In our case, a 
high packing density not necessarily provides an enhanced stability towards thiol replacement. 
Interestingly, AuNP-TA_I and AuNP_TA_III(b) showed comparable t1/2 values whereas AuNP-TA_I 
resulted to be more stable than AuNP-TA_II. The results obtained could be rationalized as follows: 
the stability of the AuNP conjugates functionalized with TA-terminated oligonucleotides towards thiol 
replacement is driven by the thermodynamic stability of the anchoring group and by the shielding that 
the peripheral groups provide to the gold core. In the case of AuNP-TA_I the negatively charged and 
bulky oligonucleotide chain lays very close to the cluster surface, thus providing steric hindrance to the 
approaching thiol. When a spacer is added, the oligonucleotide chain is moved further away, then 
reducing the interstrand repulsions due to the radial distribution of the molecules attached to AuNPs. 
Then the shielding efficiency towards ligand exchange relies on the packing quality of the spacer. 
A characteristic of AuNP cores is that they have faceted surfaces, which generate a radial structure 
for the covering monolayer [51]. These authors functionalized AuNPs with different alkylthiols 
containing an amide group at different positions. They found that the interactions between amide groups 
were highly dependent on the distance to the AuNP core [54]. In light of our results, AuNp-TA_III(c) 
and AuNp-TA_III(a) conjugates gave the highest rates of half-lives compared to the rest of the series, 
showing practically the same stability pattern. It can be reasoned that the amide bond could play an 
important role in this higher stability by providing an increase in monolayer order through hydrogen 
bonding interactions that leads t1/2 values to enhanced interactions between the neighboring alkyl or 
ethylene glycol chains (Figure 4). In the case of the AuNP-TA_III(b) conjugate, we observed similar 
t1/2 values compared with AuNP-TA_I. The effect on the stability of this spacer could be explained as 
the ability of amide groups to participate in hydrogen-bonding interactions is decreased when the 
distance to the surface increases. Finally, the lower stability observed with the AuNP-TA_II could be 
attributed to the bulky groups near the amide bond (threoninol group and phosphate linkage) (Figure 4). 
These groups may prevent effective hydrogen bonding interactions due to steric and electrostatic 
factors that could affect the packing quality of the spacer leading to a decrease in the interactions 
between the oligo(ethylene glycol) chains. 
2.4. Stability of the Thioctic Acid Derivatives to Cathepsin  
AuNPs are potential vehicles for drug delivery [55]. One of the potential applications of the 
oligonucleotide-AuNPs described in this work is their use in gene silencing. In addition of a dense and 
stable functionalization of the nanoparticles, it will be important to be able to break the linker between 
oligonucleotide and nanoparticle to release the cargo inside the cells. It is reported that the triglycine 
linker has been used for the endosomal escape of several drugs such as DOTA, doxorubicin and  
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T-2513 [33–35] because of the lability to cathepsin. Then, we decided to analyze if the same lability 
was present in the TA-oligonucleotides described in this work.  
Figure 4. Scheme showing (A) favourable interactions (in green) between amide groups and 
(B) disfavourable interactions (in red) between bulky or negatively charged substituents. 
(A) (B) 
 
Our study was focused in the determination the specificity of cathepsin B for the triglycine TA 
spacer (TA_III) versus the other TA modified oligonucleotides (TA_I and TA_II). The TA 
conjugates were incubated with Cathepsin B for 72 h and analyzed by HPLC to elucidate the 
enzymatic response (Figures 5A and Supplementary Information, S5). The HPLC profiles for the 
TA_III conjugates showed the appearance of a peak with shorter retention time, which corresponded 
to the cleavage product once analyzed by mass spectrometry (Figure 5A blue line, Supplementary 
Information, Table S4), whereas in the case of the TA_I and TA_II this peak was absent 
(Supplementary Information, Figure S5). These results confirmed that cathepsin B was able to 
cleavage the amide bonds oligonucleotides from the TA_III conjugates, however it was unable to 
liberate the oligonucleotide from TA_I and TA_II conjugates. That indicates that the activity of the 
enzyme is affected by the topology around the amide bond. To consolidate these results we 
investigated the effect of the proteinase over time with the TA_III(b). Figure 5B shows the increase of 
product release over time until a plateau was reached at 72 h as expected. Moreover, we could observe 
a different cleavage efficiency of cathepsin B between the three spacers present in the TA_III series 
(Figure 5C). We obtained the higher cleavage efficiency with the triglycine spacer (25%) followed by 
the alkyl chain and the lower cleavage was for the oligo(ethylene glycol) molecule. These results are 
consistent with the fact that the triglycine spacer has a peptide-like nature compared with the other  
two linkers.  
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Figure 5. (A) HPLC profiles obtained with TA_III(b) after 72 h in the presence (blue line) 
and in the absence (black line) of cathepsin B (CTB). ▼ stands for TA_III(b) and ■ stands for 
the product resulting from the amide-bond cleavage; (B) % amide-bond cleavage of TA_III(b) 
with time; (C) % amide-bond cleavage after 72 h of different TA-terminated oligonucleotides.  
 
3. Experimental Section  
General Methods and Materials  
All reagents were purchased from Sigma-Aldrich Spain (Tres cantos, Spain) or Fluka (Sigma-
Aldrich Química S.A., Spain) and were used without further purification. Dry solvents were purchased 
as well from Sigma-Aldrich or Fluka and used as supplied. All reactions were carried out under inert 
atmosphere of argon. All the standard phosphoramidites and ancillary reagents used for 
oligonucleotide synthesis were purchased from Applied Biosystems (Foster City, CA, USA) or Link 
Technologies (Glasgow, Scotland, UK). The benzoyl (Bz) group was used for the protection of the 
amino group of C and A. For the protection of G we used either the isobutyryl (iBu) group in the case 
of TA_I and TA_II and the dimethylformamidino group (dmf) in the case of TA_III(a)–(c). The 
hexaethylene glycol phosphoramidite (spacer phosphoramidite C18) was purchased from Glen 
Research (Sterling, VA, USA). The 6'-Fluorescein-CE-phosphoramidite and the 3'-thiol modifier C3 S-
S CPG were purchased from Link Technologies. The oligonucleotides were desalted with Sephadex G-
25 (NAP-10 or NAP-5 column, from GE Healthcare Spain (Barcelona, Spain). Cathepsin B was 
purchased from Sigma-Aldrich. Aqueous solution of citrate stabilized gold nanoparticles (9.7 nm) 
were purchased from BBI Life Sciences (Cardiff, UK) and used as received. Flash column 
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chromatography was carried out on silica gel SDS 0.063–0.2 mm/70–230 mesh. 1H- and 13C-NMR 
spectra were recorded at 25 °C on a Varian Mercury 400 MHz spectrometer (Agilent Tehcnologies, 
Santa Clara, CA, USA). 31P-NMR spectra were recorded at room temperature on a Varian Mercury 
400 MHz, operating at 162 MHz, using an internal reference using deuterated solvents. 
Tetramethylsilane (TMS) was used as an internal reference (0 ppm) for 1H spectra recorded in CDCl3 
and the residual signal of the solvent (77.16 ppm) for 13C spectra. For CD3OD or d6-DMSO the 
residual signal of the solvent was used as a reference. Chemical shifts are reported in part per million 
(ppm) in the δ scale, coupling constants (J) in Hz and multiplicity as follows: s (singlet), d (doublet), t 
(triplet), q (quadruplet), quint (quintuplet), m (multiplet) and br (broad signal). IR Spectra were 
recorded on a BOMEM MB-120 spectrometer (ABB, Frankfurt am Main, Germany). HPLC analysis 
and separations were performed using a Waters 2695 Separations Module (Milford, MA, USA) equipped 
with a Waters 2998 Photodiode Array Detector. The HPLC solvent used where: A: 5% ACN in 100 mM 
triethylammonium acetate (TEAA) (pH = 7) and solvent B: 70% ACN in 100 mM TEAA (pH = 7). 
Oligonucleotides synthesis was done in a DNA/RNA synthesizer (Applied Biosystems, Foster City, 
CA, USA) and characterized by mass spectrometry (MALDI-TOF). UV analyses were performed 
using a Jasco V-650 instrument (Easton, MD, USA) equipped with a thermoregulated cell holder. 
Fluorescent measures were recorded on a Jasco FP-6200 spectrofluorometer equipped as well with a 
thermoregulated cell holder. Electrospray ionization mass spectra (ESI-MS) were recorded on a 
Micromass ZQ instrument (Milford, MA, USA) with single quadrupole detector coupled to an HPLC, 
and high-resolution (HR) ESI-MS on an Agilent 1100 LC/MS-TOF instrument (Santa Clara, CA, USA). 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectra were recorded on 
a Voyager-DETMRP spectrometer (Applied Biosystems) in negative mode (2,4,6-trihidroxyacetophenone 
matrix with ammonium citrate as an additive). 
3.1. 4-(Dithiolan-3-yl)-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]butanamide (1) 
The compound was obtained as a mixture of two diastereoisomers. A solution of (±)-α-lipoic acid 
(344 mg, 1.67 mmol), (2R,3R)-2-aminobutane-1,3-diol (175 mg, 1.67 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI, 447 mg, 2.50 mmol), hydroxybenzotriazole (HOBt,  
339 mg; 2.50 mmol) and N,N-diisopropylethylamine (DIEA, 433 µL, 2.50 mmol) in anhydrous 
dimethylformamide (DMF, 15 mL) was prepared under argon. After stirring the reaction mixture at 
room temperature overnight, the reaction was complete as judged by TLC and then concentrated to 
dryness under reduced pressure. In order to remove the remaining DMF the residue was dissolved in 
toluene and concentrated to dryness under reduced pressure (×3). The residue was dissolved in 100 mL 
of dichloromethane (DCM) and the organic phase was washed with 50 mL 10% NaHCO3 aqueous 
solution (×2) and 50 mL of a saturated NaCl aqueous solution. The organic layer was dried over 
anhydrous magnesium sulfate and concentrated to dryness under reduced pressure. The product was 
purified by flash chromatography using as eluent pure DCM to DCM with 4% MeOH to give 
compound 1 (371 mg, 76% yield). IR (film): 3320, 2927, 1643, 1539 cm−1. 1H-NMR (400 MHz, 
CDCl3): δH = 6.21 (br, 1H, NH), 4.19 (qd, J = 6.3 Hz, 1.57 Hz; 1H, OH-CH-CH3), 3.84 (m, 2H,  
CH-CH2-OH), 3.57 (quint, J = 6.5 Hz, 1H, N-CH-CH2), 3.14 (m, 2H, S-CH2-CH2-), 2.46 (m, 1H,  
S-CH-CH2-), 2.28 (t, J = 7.4 Hz, 2H, CO-CH2-), 1.92 (m, 2H, -CH2-CH2-), 1.70 (m, 4H, -CH2-CH2-), 
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1.49 (m, 2H, CH-CH2-CH2-), 1.21 (d, J = 7.1 Hz, 3H, CH3-CH) ppm.13C-NMR (125 MHz, CDCl3): δC 
= 173.92 (NH-CO-), 69.41 (CH-O-), 65.62 (CH2-O), 56.61 (N-CH-CH2-), 54.63 (CH2-CO), 40.47 
(CH2-S), 38.70 (CH2-CH-S), 36.71, 34.82, 29.01, 25.63 (alkyl chain), 20.94 (CH3-CH) ppm. HRMS 
(ESI+): m/z calcd for C12H24NO3S2 ([M + H]+) 294.1199 found 294.1192; m/z calcd for 
C24H46N2NaO6S4 ([2M + Na]+) 609.2138 found 609.2131. 
3.2. General Procedure for the Synthesis of Amides 7a–7c  
The corresponding carboxylic acid (2.11 mmol) along with 4-nitrophenol (353 mg, 2.54 mmol) 
were dissolved in anhydrous pyridine (15 mL) under argon and the solution was cooled at 0 °C.  
Then, 524 mg (2.54 mmol) of 1,3-dicyclohexylcarbodiimide (DCC) were added under argon and the 
reaction was stirred at 0 °C for 30 min and at room temperature overnight. The precipitate was filtered 
out and the solvent was removed under reduced pressure. The residue was dissolved in toluene and 
concentrated to dryness under reduced pressure (×3). The resulting p-nitrophenyl esters 5a–5c were 
used in the next step without further purification. Then, the activated acids along with (2R,3R)-2-
aminobutane-1,3-diol (L-threoninol) (244 mg, 2.32 mmol) were dissolved in anhydrous DMF (15 mL) 
under argon and allowed to react at room temperature for 3 h. The solvent was removed under reduced 
pressure and the residue was dissolved in toluene and concentrated to dryness (×3). Crude compounds 
7a and 7c were dissolved in 100 mL of DCM and the organic phase was washed with 50 mL 10% 
NaHCO3 aqueous solution (×2) and 50 mL of a saturated NaCl aqueous solution. The organic layers 
were dried with anhydrous MgSO4 and the corresponding crudes were purified by flash 
chromatography on silica gel using as solvent pure DCM to DCM with 4% MeOH. Crude of 
compound 7b once dried with toluene was directly purified by flash chromatography on silica gel 
(crude adsorbed onto the silica, DCM/MeOH 100:5→100:15). 
3.2.1. tert-Butyl-N-[3-[2-[2-[3-[[4-[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-4-oxo-
butanoyl]amino]propoxy]ethoxy]ethoxy]propyl] carbamate (7a) 
Yield: 738 mg (69%). IR (film): 3325, 2930, 2871, 1690, 1654, 1365, 1170, 1103 cm−1. 1H-NMR 
(400 MHz, CDCl3): δH= 6.75 (br, 1H, NH), 5.07 (br, 1H, OH), 4.14 (dq, J = 6.3 Hz, 2.5 Hz; 1H,  
OH-CH-CH3), 3.84 (dd, J = 11.5 Hz, 3.5 Hz, 1H, CH-CH-OH), 3.75 (m, 2H, CH-CH-OH), 3.65  
(m, 4H, O-CH2-CH2-O), 3.59 (m, 4H, O-CH2-CH2-O), 3.55–3.47 (m, 4H, CH2-CH2-O and O-CH2-CH2), 
3.35 (m, 2H, NH-CH2-), 3.21 (m, 2H, NH-CH2), 2.61–2.54 (m, 4H, NH-CH2-CH2-CH2-O), 1.75 (2t, 
4H, CO-CH2-CH2-CO), 1.43 (s, 9H, (CH3)3-C), 1.19 (d, J = 6.4 Hz, 3H, CH3-CH) ppm.13C-NMR  
(125 MHz, CDCl3): δC = 173.54 (CO), 172.72 (CO), 172.62 (CO), 77.43 (CH3)3-C-O), 70.62  
(O-CH2-CH2-O), 70.30 (O-CH2-CH2-O), 70.29 (O-CH2-CH2-O), 69.63 (O-CH2-CH2-O), 69.59  
(CH2-O), 69.49 (CH-O-), 64.93 (CH2-O), 64.86 (CH2-O), 55.63 (N-CH-CH2), 55.62 (CH2-N), 51.03 
(CH2-N), 32.44 (CH2-CO), 32.16 (CH2-CO), 29.93 (CH2-CH2), 28.98 (CH2-CH2), 28.62 (CH3-C), 
20.57 (CH3-CH) ppm. HRMS (ESI+): m/z calcd for C23H46N3O9 ([M + H]+) 508.3229 found 508.3231; 
m/z calcd for C23H45N3NaO9 ([M + Na]+) 530.3048 found 530.3050. 
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3.2.2. N-[N'-(tert-Butoxycarbonyl)glycylglycylglycyl]-L-threoninol (7b) 
Yield: 612 mg (78%). 1H-NMR (400 MHz, DMSO-d6): δH = 8.09–8.03 (m, 2H, NH), 7.27 (d,  
J = 8.8 Hz, 1H, NH), 6.97 (t, J = 5.6 Hz, 1H, NH), 4.61–4.54 (br, 2H, OH), 3.85–3.81 (m, 1H,  
OH-CH-CH3), 3.72–3.70 (m, 4H, NH-CH2-CO), 3.63–3.58 (m, 2H, NH-CH-CH2), 3.56 (d, J=6.0 Hz, 2H, 
NH-CH2-CO), 3.44–3.40 (m, 1H, OH-CH(A)H(B)-CH)), 3.33–3.28 (m, 1H, OH-CH(A)H(B)-CH)),1.36 (s, 
9H, (CH3)3-C), 0.97 (d, J = 6.4 Hz, 3H, CH3-CH-CH) ppm.13C-NMR (125 MHz, DMSO-d6):  
δC = 170.58 (NH-CO), 169.67 (NH-CO), 169.37 (NH-CO), 156.50 (O-CO-NH), 78.83 (CH3-C), 64.88 
(CH3-CH), 61.12 (OH-CH2-CH), 56.43 (NH-CH-CH), 43.99 (NH-CH2-CO), 42.77 (NH-CH2-CO), 42.70 
(NH-CH2-CO), 28.87 (CH3-C), 20.73 (CH3-CH). HRMS (ESI+): m/z: calcd. for C15H29N4O7([M + H]+) 
377.2036 found 377.2031; m/z: calcd. for C15H28N4NaO7 ([M + Na]+) 399.1856 found 399.1856. 
3.2.3. tert-Butyl-N-[8-[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-8-oxo-octyl]carbamate (7c) 
Yield: 701 mg (96%). IR (film): 3323, 2974, 2930, 2858, 1689, 1652, 1525, 1366, 1251, 1171 cm−1. 
1H-NMR (400 MHz, CDCl3): δH = 6.30 (br, 1H, NH), 4.56 (br, 1H, OH), 4.19 (qd, J = 6.4 Hz, 1.9 Hz, 
1H, OH-CH-CH3), 3.83 (m, 3H, CH-CH2-OH), 3.07 (m, 2H, CH2-NH), 2.26 (t, J = 7.3 Hz, 2H, CH2-CH2), 
1.66 (m, 2H, alkyl chain), 1.44 (s, 9H, (CH3)3-C), 1.33 (m, 6H, alkyl chain), 1.21 (d, J = 6.3 Hz, 3H, 
CH3-CH) ppm. 13C-NMR (125 MHz, CDCl3): δC = 174.31 (CO-NH), 77.43 (CH3-C-O), 69.43 (CH-O), 
65.62 (CH2-O), 54.61 (N-CH-CH2), 40.63 (CH2-CO), 36.86, 29.94, 29.04, 28.62, 26.54, 25.57  
(alkyl chain), 20.82 (CH3-CH-) ppm. HRMS (ESI+): m/z calcd for C17H35N2O5 ([M + H]+) 347.2540 
found 347.2543; m/z calcd for C34H68N4NaO10 ([2M + Na]+) 715.4828 found 715.4824. 
3.3. General Procedure for the Introduction of Lipoic Acid Residue: Synthesis of Compounds 8a–8c 
Using the same experimental procedure as described above for the activation of carboxylic acids, a 
solution of (±)-α-lipoic acid (322 mg, 1.56 mmol) and p-nitrophenol (239 mg, 1.72 mmol) in 
anhydrous pyridine (15 mL) was prepared under argon. Then, the solution was cooled to 0 °C and 
DCC (354 mg, 1.72 mmol) was added under argon. The reaction was stirred at 0 °C for 30 min and at 
room temperature overnight. The precipitate was filtered out and the solvent was removed under 
reduced pressure. The residue was dissolved in toluene and concentrated to dryness under reduced 
pressure (×3). Then the crude was dissolved in DCM (75 mL) and the organic phase was washed with 
5% aqueous NaHCO3 (2 × 30 mL) and saturated aqueous NaCl (30 mL). The organic phase was dried 
(MgSO4) and concentrated to dryness under reduced pressure and then dried in a desiccator.  
The p-nitrophenyl ester 6 (yellow solid) was used in the next step without further purification. Then, 
the corresponding protected amines 7a–7c (1.30 mmol) were subjected to acidic conditions 
(DCM/TFA 10%) in order to obtain the respective free amines as trifluoroacetate salts. Each protected 
amine was dissolved in DCM (20mL) and TFA (2 mL) was added slowly at room temperature. Stirring 
was continued until TLC showed the consumption of all starting material (usually 1–1.5 h), then the 
mixture was concentrated to dryness under reduced pressure. The residue was dissolved in toluene and 
concentrated to dryness under reduced pressure. This operation was repeated three times to remove 
traces of TFA to yield the TFA salt of the deprotected amino compound (colorless oil). The residue 
was dried in vacuo and used in the next step without further purification. Then, each deprotected amino 
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compound was dissolved in anhydrous DMF (10 mL) and anhydrous DIEA (0.94 mL, 5.20 mmol) was 
added under argon. The solution was added dropwise under argon to a prepared solution (anhydrous 
DMF, 10 mL) of the activated lipoic acid derivative. The mixture was allowed to react at room 
temperature and under argon overnight. The solvent was removed under reduced pressure and the residue 
was dissolved in toluene (3 × 10 mL) and concentrated to dryness. Crudes of compounds 8a and 8c were 
dissolved into 75 mL of dichloromethane and were washed with 5% NaHCO3 (3 × 30 mL) and with a 
saturated aqueous solution NaCl (30 mL). The organic layers were dried with anhydrous MgSO4 and 
the corresponding crudes were purified by flash chromatography on silica gel using as solvent pure 
DCM to DCM with 4% MeOH. Crude of 8b once dried with toluene was directly purified by flash 
chromatography on silica gel (crude adsorbed onto the silica, DCM/MeOH 100:5→100:15). 
3.3.1. N'-[3-[2-[2-[3-[4-(Dithiolan-3-yl)butanoylamino]propoxy]ethoxy]ethoxy]propyl]-N-[(1R,2R)-2-
hydroxy-1-(hydroxymethyl)propyl]butanediamide (8a) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 565 mg (73%). IR (film): 
3320, 2928, 1652, 1539, 1456, 1216, 1130 cm−1. 1H-NMR (400 MHz, CDCl3): δH = 6.73 (br, 1H, NH), 
6.65 (br, 1H, OH), 6.43 (br, 1H), 4.16 (dq, J = 6.3 Hz, 2.6 Hz, 1H, OH-CH-CH3), 3.88 (dd, J = 11.3 Hz, 
3.4 Hz, 1H, CH-CH-OH), 3.75 (m, 2H, CH-CH-OH), 3.65 (m, 4H, O-CH2-CH2-O), 3.61 (m, 4H,  
O-CH2-CH2-O), 3.55 (m, 4H, CH2-CH2-O and O-CH2-CH2), 3.35 (m, 4H, 2 NH-CH2-), 3.18 (m, 2H, 
S-CH2-CH2), 3.14 (m, 2H, CH2-NHCO), 2.64 (m, 1H, S-CH-CH2), 2.49 (m, 4H, NH-CH2-CH2-CH2-O), 
2.17 (t, J = 7.6 Hz, 2H, CH2-CH2-), 1.74 (m, 8H, CO-CH2-CH2-CO and alkyl residue), 1.44 (d, J = 6.9 Hz, 
3H, CH3-CH), 1.38 (d, J = 6.7 Hz, 3H, CH3-CH) ppm.13C-NMR (125 MHz, CDCl3): δC = 173.72 
(CO), 173.35 (CO), 172.51 (CO), 70.73 (O-CH2-CH2-O), 70.62 (O-CH2-CH2-O), 70.20 (O-CH2-CH2-O), 
70.19 (O-CH2-CH2-O), 70.18 (CH2-O), 70.08 (CH2-O), 68.89 (CH-O), 64.54 (CH2-O), 56.75 (CH2-CO), 
55.71 (CH2-CO), 41.86 (CH2-CH-N), 40.43 (CH2-S), 38.62 (CH2-N), 38.16 (CH2-N), 37.82 (CH2-CH-S), 
36.67 (CH2-CO), 34.88 (S-CH2-CH2-CH-S) 37.85 (S-CH-CH2), 36.63 (-CH2-CH2-), 34.85 (-CH2-CH2-), 
32.31 (NH-CH2-CH2-), 32.21 (-CH2-CH2-CH2-O), 32.09, 29.34, 29.05 (CH3-CH) ppm. HRMS (ESI+): 
m/z calcd for C26H50N3O8S2 ([M + H]+) 596.3034, found 596.3038. 
3.3.2. N-[N'-{5-(1,2-Dithiolan-3-yl)pentanoyl}glycylglycylglycyl]-L-threoninol (8b) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 459 mg (76%). 1H-NMR 
(400 MHz, CD3OD): δH = 3.91–3.86 (m, 1H, OH-CH-CH3), 3.82–3.81 (m, 2H, NH-CH2-CO), 3.79 (d, 
J = 2.8 Hz, 4H, NH-CH2-CO), 3.74–3.70 (m, 1H, NH-CH-CH2), 3.58–3.53 (m, 1H, OH-CH(A)H(B)-CH), 
3.51–3.46 (m, 1H, OH-CH(A)H(B)-CH), 3.13–2.97 (m, 3H, S-CH2-CH2 and S-CH-CH2), 2.41–2.33 (m, 
1H, S-CH-CH(A)H(B)-CH2), 2.20 (t, J = 7.4 Hz, 2H, CH2-CH2-CO-NH), 1.84–1.76 (m, 1H,  
S-CH-CH(A)H(B)-CH2), 1.68–1.50 (m, 4H, alkyl chain), 1.42–1.35 (m, 2H, alkyl chain), 1.05 and 1.04 
(2d, J = 6.4 Hz and J = 6.4 Hz, 3H, CH3-CH) ppm. 13C-NMR (125 MHz, DMSO-d6): δC = 173.30 
(NH-CO), 170.36 (NH-CO), 169.70 (NH-CO), 169.41 (NH-CO), 64.91 (CH3-CH), 61.13 (OH-CH2-CH), 
56.79 (NH-CH-CH2-), 56.45 (S-CH-CH2), 46.40 (S-CH2-CH2), 43.96 (NH-CH2-CO), 42.74 (NH-CH2-
CO), 42.72 (NH-CH2-CO), 38.77 (S-CH-CH2), 35.63 (CH2-CH2-CO-NH), 34.81 (CH2 alkyl chain), 
29.01 (CH2alkyl chain), 25.5 (CH2 alkyl chain), 20.72 (CH3-CH) ppm. HRMS (ESI+): m/z calcd for 
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C18H33N4O6S2 ([M + H]+) 465.1842, found 465.1848; m/z calcd for C18H32N4NaO6S2 ([M + Na]+) 
487.1661 found 487.1658. 
3.3.3. 8-[4-(Dithiolan-3-yl)butanoylamino]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]octan-
amide (8c) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 231 mg (41%). IR (film): 
3304, 2927, 2855, 1646, 1557, 1540, 1457, 1201 cm−1. 1H-NMR (400 MHz, CDCl3): δH = 6.37 (br, 
1H, NH), 5.59 (br, 1H; OH), 4.18 (qd, J = 6.2 Hz, 1.5 Hz, 1H, OH-CH-CH3) 3.84 (m, 2H, CH-CH2-OH), 
3.57 (m, 1H,CH-CH2-OH), 3.23 (m, 2H, S-CH2-CH2-), 3.13 (m, 2H, CH2-NHCO), 2.47 (m, 1H,  
S-CH-CH2-), 2.27 (d, J = 7.3 Hz, 2H, -CH2-CH2, lipoic residue), 2.17 (t, J = 7.0 Hz, 2H, -CH2-CH2-), 
1.91 (m, 2H, -CH2-CH2-), 1.67 (m, 6H, alkyl chain), 1.48 (m, 2H, alkyl chain), 1.33 (m, 8H, alkyl chain), 
1.21 (d, J = 6.4 Hz, 3H, CH3-CH) ppm.13C-NMR (125 MHz, CDCl3): δC = 174.45 (CONH), 173.44 
(CONH), 69.69 (CH-O-), 65.72 (CH2-O), 56.62 (NH-CH-CH2-), 54.65 (NH-CH2), 45.85 (CH2-CO), 
40.47 (CH2-CO), 39.55 (CH2-S), 38.72 (CH2-CH-S), 36.81, 34.72, 29.42, 29.07, 28.76, 28.40, 28.39, 
26.37, 25.72 (alkyl chain), 20.72 (CH3-CH) ppm. HRMS (ESI+): m/z calcd for C20H39N2O4S2 ([M + H]+) 
435.2346, found 435.2351; m/z calcd for C40H76N4NaO8S4 ([2M + Na]+) 869.4619 found 869.4615. 
3.4. General Procedure for the Preparation of the DMT Protected Compounds 2 and 9a–9c  
Each diol (0.80 mmol) was dried by evaporation of anhydrous acetonitrile (ACN) under reduced 
pressure (×2). Then to a solution of the corresponding diol in anhydrous pyridine (15 mL) at 0 °C, 
DIEA (217 µL, 1.20 mmol), 4,4'-dimethoxyltritylchloride (DMT-Cl) (297 mg, 0.88 mmol) and 
dimethylaminopyridine (DMAP) (catalytic amount) were added. After 15 min, the mixture was 
allowed to reach room temperature. Then the reaction was stirred for an additional 24 h and finally was 
quenched with methanol except for diol 7b. In this case DMT-Cl (135 mg, 0.40 mmol), DIEA (109 µL 
0.60 mmol) and DMAP (catalytic amount) were dissolved in dry pyridine (5 mL) and were added to 
the mixture. The solution was stirred at room temperature for 6 h and quenched with methanol.  
The solvent was evaporated under reduced pressure. The residue was dissolved in toluene (3 × 10 mL) 
and concentrated to dryness. Then, the resulting crude was dissolved in dichloromethane (100 mL) and 
the organic phase was washed with 5% aqueous NaHCO3 (50 mL) and with saturated aqueous NaCl 
(50 mL). The solvent was evaporated and the residue was purified by flash chromatography on silica gel. 
The column was packed using a 1% triethylamine (TEA) solution in DCM. Compounds 2, 9a and 9c 
were eluted with a gradient of MeOH from 0% to 4% in DCM and compound 9b was eluted with a 
gradient of MeOH from 0% to 10% in DCM. 
3.4.1. N-[(1R,2R)-1-[[bis(4-Methoxyphenyl)phenylmethoxy]methyl]-2-hydroxypropyl]-5-(dithiolan-3-
yl)pentanamide (2) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 295 mg (62%). IR (film): 
3176, 2927, 1646, 1508, 1249, 1175, 1033 cm−1. 1H-NMR (400 MHz, CDCl3): δH = 7.67 (tt, J = 7.56 Hz, 
7.7 Hz; 1H,CHarom), 7.36 (m, 2H, (CHarom), 7.27 (m, 8H,CHarom), 6.84 (d, J = 8.8 Hz, 2H,CHarom), 6.7 
(br, 1H, NH), 4.07 (m, 1H, OH-CH-CH3), 3.92 (m, 1H, CH-CH-OH), 3.79 (s, 6H, 2 OCH3), 3.72 (m, 
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1H, CH-CH-OH), 3.56 (m, 1H, N-CH-CH2), 3.41 (dd, J = 9.6 Hz, 4.2 Hz, 1H, S-CH-CH2-), 3.30 (dd,  
J = 9.4 Hz, 4.2 Hz, 1H, S-CH-CH2-), 3.17 (m, 2H, S-CH2-CH2-), 3.00 (br, 1H, OH), 2.45 (m, 1H,  
S-CH-CH2-), 2.23 (t, J = 7.4 Hz; 2H, CO-CH2), 1.90 (m,2H, -CH2-CH2-), 1.69 (m, 4H, alkyl residue), 
1.49 (m, 2H, alkyl residue), 1.13 (d, J = 6.4 Hz, 3H, CH-CH3) ppm.13C-NMR (125 MHz, CDCl3):  
δC = 173.25 (CO), 158.84 (Carom), 150.06 (Carom), 144.51 (Carom), 136.14 (Carom), 135.73 (Carom), 
135.66 (Carom), 135.53 (CHarom), 130.01 (CHarom), 128.20 (CHarom), 128.18 (CHarom), 127.23 (CHarom), 
123.92 (CHarom), 113.57 (CHarom), 87.03 (C-Carom), 68.94 (CH-O-), 65.55 (CH2-O), 56.57 (N-CH-CH2-), 
55.63 (OCH3), 55.49 (OCH3), 53.54 (COCH2), 40.43 (CH2-S), 38.64 (CH2-CH-S), 36.73, 34.93, 29.16, 
25.76 (alkyl chain), 20.18 (CH3-CH) ppm. HRMS (ESI+): m/z calcd for C66H82N2NaO10S4 ([2M + Na]+) 
1213.4745, found 1213.4745. 
3.4.2. N-[(1R,2R)-1-[[bis(4-Methoxyphenyl)phenylmethoxy]methyl]-2-hydroxypropyl]-N'-[3-[2-[2-[3-
[5-(dithiolan-3-yl)pentanoylamino]propoxy]ethoxy]ethoxy]propyl]butanediamide (9a) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 467 mg (65%). IR (film): 
2929, 2662, 1653, 1608, 1545, 1508, 1463, 1393, 1249, 1178, 1131, 1095, 1033, 753 cm−1. 1H-NMR 
(400 MHz, CDCl3): δH = 7.39 (d, J = 7.3 Hz, 2H, CHarom), 7.29 (m, 6H, CHarom), 7.21 (d, J = 7.3 Hz, 
1H, CHarom), 6.84 (d, J = 8.9 Hz, 4H,CHarom), 6.69 (br, 1H, NH), 6.64 (br, 1H, NH), 6.49 (br, 1H, NH), 
4.07 (m, 1H, CH3-CH-OH), 3.91 (m, 3H, N-CH-CH2-OH), 3.79 (s, 6H, 2 OCH3), 3.64 (m, 8H,  
2 O-CH2-CH2-O), 3.59–3.54(m, 4H, O-CH2-CH2-O), 3.34 (m, 4H, 2 NH-CH2-), 3.09 (m, 4H,  
S-CH2-CH2 and CH2-NHCO), 2.52 (m, 5H, S-CH-CH2- and NH-CH2-CH2-CH2-O), 2.14 (t, J = 7.2 Hz, 
2H, CO-CH2), 1.85–1.49 (m, 8H, alkyl residues), 1.12 (2d, J = 6.4 Hz, 6H, 2 CH3-CH) ppm. 13C-NMR 
(125 MHz, CDCl3): δC = 172.83 (CO), 172.74 (CO), 172.06 (CO), 158.55 (Carom), 145.36 (Carom), 
135.87 (Carom), 135.79 (Carom), 130.06 (CHarom), 129.89 (Carom), 127.82 (CHarom), 127.79 (CHarom), 
126.43 (CHarom), 113.44 (CHarom), 86.54 (C-O), 70.57 (CH-O-), 70.49 (CH-O-), 70.05 (CH-O-), 69.98 
(CH-O-), 69.88 (CH-O-), 68.26 (CH-O-), 64.8 (CH-O-), 56.44 (OCH3), 55.23 (OCH3), 54.06 (CH-N), 
53.64 (CH-N), 41.93 (CH2-S), 38.46 (CH2-S), 37.83 (CH2-CH-S), 36.37(COCH2), 34.68 (N-CH2), 
31.95 (N-CH2), 31.72, 29.62, 29.08, 28.96, 28.86, 25.43, 19.82, 17.33 (alkyl residue), 17.31 (CH3CH) 
ppm. HRMS (ESI+): m/z calcd for C26H50N3O8S2 ([M + H-DMT]+) 596.3033, found 596.3032. 
3.4.3. O1-(4, 4'-Dimetoxytriphenylmethyl)-N-[N'-{5-(1,2-dithiolan-3-yl)pentanoyl}glycylglycylglycyl]-
L-threoninol (9b) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 325 mg (53%). 1H-NMR 
(400 MHz, DMSO-d6): δH = 8.13 (t, J = 5.6 Hz, 1H, CH2-NH-CO), 8.07–8.04 (m, 2H, CH2-NH-CO), 
7.50 (d, J = 7.6 Hz, CH-NH-CO), 7.37–7.17 (m, 9H, CHarom), 6.86 (d, J = 8.8 Hz, 4H, CHarom), 4.54 
(d, J = 5.2 Hz, 1H, OH-CH), 3.95–3.90 (m, 1H, OH-CH-CH3), 3.89–3.82 (m, 1H, NH-CH-CH2),  
3.78–3.69 (m, 12H, 2 OCH3 and 3 NH-CH2-CO), 3.61–3.53 (m, 1H, S-CH-CH2), 3.18–3.02 (m, 3H, 
DMTO-CH(A)H(B)-CH and S-CH2-CH2), 2.86–2.82 (m, 1H, DMTO-CH(A)H(B)-CH), 2.41–2.34 (m, 1H, 
S-CH-CH(A)H(B)-CH2), 2.12 (t, J = 7.2 Hz, 2H, CH2-CH2-CO-NH), 1.88–1.79 (m, 1H, S-CH-CH(A)H(B)-CH2), 
1.68–1.59 (m, 2H, alkyl chain), 1.54–1.46 (m, 2H, alkyl chain), 1.36–1.31 (m, 2H, alkyl chain), 0.94 
(d, J = 6.0 Hz, 3H, CH3-CH) ppm. 13C-NMR (125 MHz, DMSO-d6): δC = 173.25 and 173.16 (NH-
CO)(*), 170.31, 170.29, 170.23 and 170.21 (NH-CO)(*), 169.64, 169.62, 169.57 and 169.55 (NH-
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CO)(*), 169.29, 169.23 and 169.21 (NH-CO)(*), 158.65 (Carom), 145.76 (Carom), 136.49 (Carom), 136.45 
(Carom), 130.37 (CHarom), 128.45 (CHarom), 128.39 (CHarom), 127.22 (CHarom), 113.80 (CHarom), 85.82 
(C-O), 65.44 and 65.33 (CH3-CH)(*), 63.39 (DMTO-CH2-CH), 56.79 (S-CH-CH2), 55.69 (O-CH3), 
54.74, 54.72, 54.66 and 54.63 (NH-CH-CH)(*), 46.24 (S-CH2-CH2), 42.77 and 42.75 (NH-CH2-CO)(*), 
42.66 and 42.63 (NH-CH2-CO)(*), 42.47 and 42.45 (NH-CH2-CO)(*), 38.77 (S-CH-CH2), 35.64 and 35.59 
(CH2-CH2-CO-NH)(*), 34.81 (CH2 alkyl chain), 29 01 (CH2 alkyl chain), 25.51 (CH2 alkyl chain), 
20.87 and 20.81 (CH3-CH)(*) ppm. HRMS (ESI+): m/z calcd for C39H50N4NaO8S2 ([M + Na]+) 
789.2968, found 789.2960; m/z calcd for C18H33N4O6S2 ([M-DMT+H]+) 465.1842, found 465.1845; 
m/z calcd for C18H32N4NaO6S2 ([M-DMT + Na]+) 487.1661 found 487.1661. (*)Multiple peaks 
observed due to rotamers of the amide bond. 
3.4.4. N-[(1R,2R)-1-[[bis(4-Methoxyphenyl)phenylmethoxy]methyl]-2-hydroxypropyl]-8-[5-(dithiolan-
3-yl)pentanoylamino]octanamide (9c) 
The compound was obtained as a mixture of two diastereoisomers. Yield: 277 mg (47%). IR (film): 
3019, 2925, 1652, 1058, 1215 cm−1. 1H-NMR (400 MHz, CDCl3): δH = 7.67 (tt, J = 7.6 Hz, 1.8 Hz, 
1H, CHarom), 7.39 (m, 2H, CHarom), 7.27 (m, 8H, CHarom), 6.83 (d, J = 8.2 Hz, 2H, CHarom), 6.1 (br, 1H, 
NH), 4.08 (m, 1H, OH-CH-CH3), 3.94 (m, 1H, CH-CH-OH), 3.78 (s, 6H, 2 OCH3), 3.56 (m, 1H,  
N-CH-CH2), 3.39 (dd, J = 9.5 Hz, 4.5 Hz, 1H, CH-CH-OH), 3.23 (m, 2H, S-CH2-CH2-), 3.10 (m, 2H, 
CH2-N), 2.42 (m, 1H, S-CH-CH2-), 2.21 (t, J = 7.5 Hz, 2H, CO-CH2), 2.14 (t, J = 7.5 Hz, 2H, 
COCH2), 1.89 (m, 2H, -CH2-CH2-), 1.64 (m, 6H, alkyl residue), 1.45 (m, 4H, alkyl residue), 1.32 (m, 
6H, alkyl residues), 1.12 (d, J = 6.3 Hz, 3H, CH3-CH) ppm. 13C-NMR (125 MHz, CDCl3): δC = 173.63 
(CO), 172.91 (CO), 158.82 (Carom), 149.93 (Carom), 144.66 (Carom), 136.24 (Carom), 135.84 (Carom), 
135.66 (Carom), 130.21 (CHarom), 130.19 (CHarom), 128.20 (CHarom), 128.18 (CHarom), 127.21 (CHarom), 
124.05 (CHarom), 113.57 (CHarom), 86.86 (C-Carom), 68.55 (CH-O-), 65.37 (CH2-O), 56.73 (N-CH-CH2-), 
55.46 (OCH3), 53.63 (COCH2), 40.47 (CH2-S), 39.65 (CH2-S), 38.63 (CH2-CH-S), 36.94 (COCH2), 
36.69 (NCH2), 34.83, 29.76, 29.20, 29.19, 29.08, 26.83, 25.88, 25.68 (alkyl residues), 20.25 (CH3CH) 
ppm. HRMS (ESI+): m/z calcd for C41H56N2NaO6S2 ([M + Na]+) 759.3472, found 759.3475; m/z calcd 
for C82H112N4NaO12S4 ([2M + Na]+) 1495.7052, found 1495.7032. 
3.5. Functionalization of CPG Solid Supports 4 and 11a–11c  
The DMT derivatives (2, and 9a–9c) were incorporated on a long-chain alkylamine-controlled pore 
glass support (LCAA-CPG) as described [56] using their corresponding hemisuccinate derivatives as 
follows. The DMT derivative (0.05 mmol) was dried by evaporation with anhydrous ACN under 
reduced pressure. The residue was dissolved in anhydrous pyridine (5 mL) under argon. Succinic 
anhydride (26 mg, 0.26 mmol) and DMAP (2.5 mg, 0.02 mmol) were dissolved in 1 mL of pyridine 
and added to the solution. The solution was stirred overnight at room temperature. The solvent was 
removed under reduced pressure and the residue was dissolved in toluene (3 × 10 mL) and 
concentrated to dryness. The resulting material was dissolved in dichloromethane (20 mL). The 
solution was washed with 0.1 M sodium monophosphate (15 mL) and saturated aqueous NaCl (15 mL). 
The organic layer was dried over anhydrous MgSO4, filtered and evaporated to dryness. Yellowish oils 
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were obtained in each case. The resulting hemisuccinates 3 and derivatives10a–10c were used in the 
next step without further purification. 
Amino-LCAA-CPG (CPG New Jersey, 73 μmol amino/g, 200 mg) was placed into a polypropylene 
syringe fitted with a polypropylene disc and washed sequentially with DMF, MeOH, THF, DCM and 
ACN (2 × 5 mL). Then, a solution of the appropriate hemisuccinate (25 µmol) and triethylamine  
(25 µL, 175 µmol) in anhydrous ACN (500 µL) was prepared. The solution was added to the support 
and then a solution of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) 
(56 mg, 175 µmol) in anhydrous ACN (300 µL) was added. The mixture was left to react for 1 h.  
The support was washed with DMF, MeOH, DCM and ACN (2 × 5 mL). The coupling procedure was 
repeated once more if needed and the functionality of the resin was determined by DMT 
quantification. The functionalization obtained in each case were f = 19.0 μmol/g for solid support 4, 
18.5 μmol/g for 11a, 25.3 μmol/g for 11b and 15.1 μmol/g for 11c. Finally, each solid support was 
treated with a mixture of Ac2O/DMF (1:1, 500 μL) to cap free amino groups. 
3.6. N-[(1R,2R)-1-{[bis(4-Methoxyphenyl)phenylmethoxy]methyl}-2-[2-cyanoethoxydiisopro-
pylamino)phosphanyl]oxypropyl]-4-(dithiolan-3-yl)butanamide (12) 
Compound 2 (100 mg, 0.13 mmol) was dried by evaporation of anhydrous ACN (3 × 10 mL) under 
reduced pressure and dried in a desiccator for one hour. Then, compound 2 was dissolved in anhydrous 
DCM (2 mL) and DIEA (69 µL, 0.39 mmol) was added dropwise at room temperature. The solution 
was cooled at 0 °C and 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (46 µL, 0.19 mmol) 
was added dropwise with a syringe. Reaction was stirred 5 min at 0 °C and 1 h at room temperature. 
After this time the reaction was complete as judged by TLC. Then, DCM was added  
(10 mL) and organic layer was washed with a 5% NaHCO3 aqueous solution (1 × 5 mL) and brine  
(1 × 5 mL). Finally, solvent was evaporated and the crude was purified by flash chromatography 
(Hex/AcOEt 20% to 50%) to give compound 12 (80 mg, 77% yield). The compound was obtained as a 
mixture of diastereoisomers. IR (film): 2966, 2929, 2360, 2342, 1673, 1607, 1508, 1249, 1177, 1034 cm−1. 
1H-NMR (400 MHz, CDCl3): δH = 7.38 (m, 2H), 7.26 (m, 7H), 6.29 (m, 4H), 5.80 (broad s, NH), 4.30 
(m, 1H), 4.23 (m, 5H), 3.75 (s, 6H, 2 OCH3), 3.47 (m, 4H), 3.14 (m, 2H), 2.70 (m, 2H), 2.36 (m, 1H), 
2.17 (m, 2H), 1.90 (m, 2H), 1.63 (m, 4H), 1.30–1.15 (m, 15H) ppm; 13C-NMR (125 MHz, CDCl3)  
δC = 173.3 (CO), 158.4 (Carom), 144.8 (Carom), 135.9 (Carom), 130.1 (Carom), 130.0 (Carom), 129.9 (Carom), 
128.2 (CHarom), 128.0 (CHarom), 127.7 (CHarom), 126.7 (CHarom), 113.0 (CN), 86.0 (C-Carom), 68.7 (CH-O), 
65.7 (CH2-O), 65.3 (P-O-CH2), 58.3 (N-CH-CH2), 58.1 (N-CH-CH2), 55.2 (OCH3), 53.3 (COCH2), 
43.0 (CH2-S), 40.2(CH-N), 38.4 (CH2-CH-S), 36.5, 34.6, 29.6, 24.7 (alkyl chain), 24.2 (CH3-CH), 22.6 
(CH3-CH), 19.6 (CH2-CN) ppm; 31P-NMR (163 MHz, CDCl3) δP = 148.0 ppm; HRMS (ESI+): m/z 
calcd for C42H59N3O6PS2 ([M+H]+) 796.3583, found 796.3577. 
3.7. Synthesis of the Model Oligonucleotides (T12)TA_I, and (T12)TA_III(a)–(c) 
The TA terminated dodecathymidine oligonucleotides (T12)TA_I, and (T12)TA_III(a)-(c) (5'-TTT 
TTT TTT TTT-X-3', X being a TA modification) were synthesized on a DNA/RNA synthesizer 
(Applied Biosystems) on a 0.2 µmol scale using the corresponding modified CPG solid supports. The 
solid support 4 was used to synthesize the oligonucleotide (T12)TA_I and the corresponding solid 
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supports 11(a)–(c) for oligonucleotides (T12)TA_III(a)–(c). The last DMT group was removed at the 
end of the synthesis. The resulting oligonucleotides were deprotected and cleaved from the solid 
supports with aqueous concentrated ammonia using three different conditions: (i) at room temperature 
for 4 h; (ii) at 55 °C for 1 h and (iii) at 55 °C overnight. The mixtures were filtered and ammonia 
solutions were concentrated to dryness. The resulting products were analyzed by HPLC. Solvent A: 
5% ACN in 100 mM triethylammonium acetate (TEAA) (pH = 7) and solvent B: 70% ACN in 100 mM 
TEAA (pH = 7). Column: XBridgeTM OST C18 column; (4.6 × 50 mm, 2.5 µm). Flow rate: 1 mL/min. 
Conditions: 10 min of linear gradient from 5% to 35% of B. The isolated products were analyzed by 
mass spectrometry (MALDI-TOF) (Supplementary Information, Table S1). 
3.8. Synthesis of 3'-TA-Modified Oligonucleotides and the 5'-Fluorescently Labeled 3'-TA-Modified 
Oligonucleotide Probes 
The thioctic acid terminated 21mer oligonucleotides TA_I, TA_II and TA_III(a)-(c) (5'-CGG 
AGG TAC ATT CGA CTT GA-X-3', where X was a TA residue) were synthesized a 1 µmol scale 
using the corresponding modified CPG solid supports. Oligonucleotide TA_II was synthesized using 
the solid support 4 once the commercially available spacer 18-O-dimethoxytritylhexaethyleneglycol,  
1-[(2-cyanoethyl)-(N,N-diisopropyl)] phosphoramidite was incorporated. Once the synthesis of TA_I, 
TA_II and TA_III(a)–(c) was completed, each solid support was divided in two. The last DMT group 
was removed at the end of the synthesis. One half was deprotected and the other half was used for the 
synthesis of the corresponding fluorescently labeled oligonucleotides (F)TA_I, (F)TA_II and 
(F)TA_III(a)–(c). Coupling yields were >97%. TA_I, TA_II and their corresponding fluorescently 
labeled versions were treated with aqueous concentrated ammonia at 55 °C for 12 h to cleave the 
products from the supports and remove the Bz and iBu groups. The TA_III series were treated with 
aqueous concentrated ammonia at room temperature for 4 h to cleave the products from the supports 
and remove the Bz and dmf groups. The mixtures were filtered and ammonia solutions were 
concentrated to dryness. The resulting oligonucleotides were desalted and purified by HPLC using the 
same solvents described above. Column: XBridgeTM OST C18 semipreparative column (10 × 50 mm, 
2.5 µm). Flow rate: 3 mL/min. Conditions: 10 min of linear gradient from 0% to 30% of B for non 
fluorescently labeled oligonucleotides and 10 min. of linear gradient from 6% to 40% for the 
corresponding fluorescently labeled oligonucleotides. The pure fractions were combined and 
evaporated to dryness. The resulting oligomers were analyzed by mass spectrometry, UV/Vis 
spectroscopy and HPLC as well using the conditions and gradients described above but using an 
analytic column (XBridgeTM OST C18 (4.6 × 50 mm, 2.5 μm). Flow rate: 1 mL/min), (Table S3, SI). 
The yields obtained ranged from 33% to 49%. 
3.9. Synthesis of a 5'-TA-Modified Oligonucleotide 
The thioctic acid terminated 21mer oligonucleotide 5'TA_I, (5'-X-CGG AGG TAC ATT CGA 
CTT GA-3', where X was a TA residue) was synthesized on a 0.2 µmol scale employing LV200® 
polystyrene supports. Phosphoramidite 12 was used to incorporate the TA derivative. The DMT 
determination showed that the efficiency of coupling of the phosphoramidite was >90%. The last DMT 
group was removed at the end of the synthesis. The solid support was treated with aqueous 
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concentrated ammonia at 55 °C for 12 h. and oligonucleotide 5'TA_I purification by HPLC was using 
the same protocol as described above. (Table S3, SI). The purified oligonucleotide was obtained in 
51% yield. 
3.10. Synthesis of 3'-Alkylthiolated-Modified Oligonucleotides and the 5'-Fluorescently Labeled 3'-
Alkylthiolated Modified Oligonucleotide Probes 
The 3'-disulfide-modified oligonucleotide ALK_DS (5'-CGG AGG TAC ATT CGA CTT GA-Y-3') 
(Y stands for 3'- linear alkyldisulfide or alkylthiol modifications) was synthesized on a 1 µmol scale 
using the 3'-Thiol modifier C3 S-S CPG following the procedure described previously. The last DMT 
group was removed at the end of the synthesis. As well, once the synthesis was completed, half of the 
solid support was used to incorporate the fluorescent dye at the 5'-termini to obtain the fluorescently 
labeled (F)ALK_DS analogue. Each solid support was treated with aqueous concentrated ammonia at 
55 °C for 12 h. Work-up was similar as described above. The oligonucleotides were analyzed by 
HPLC using the conditions described above and characterized by mass spectrometry (MALDI-TOF) 
and UV/Vis spectroscopy (Table S3, SI) and used without further purification. The yields obtained 
were 74% for ALK_DS and 72% for (F)ALK_DS. The 3'-thiol-modified oligonucleotide ALK_SH and 
its fluorescently labeled version (F)ALK_SH were obtained from the corresponding disulfide 
oligonucleotides ALK_DS and (F)ALK_DS respectively by thiol deprotection [44,45]. The experimental 
procedure is as follows: disulfide oligonucleotides (5 OD260) were dissolved in 300 µL of an aqueous 
solution 0.1 M TEAA (pH = 7). Then, 34 L of an aqueous solution 0.1 M of tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP·HCl) were added to the solution and allowed to react at 55 °C overnight.  
Under these conditions, the disulfide group was completely removed and the deprotected thiol 
oligonucleotides (ALK_SH and (F)ALK_SH, respectively) were purified with Sephadex G-25  
(NAP-5 column) and used in the next step without further purification. 
3.11. Functionalization of Gold Nanoparticles 
Colloidal gold nanoparticles (9.7 nm diameter) were functionalized with the TA-modified 
oligonucleotides (TA_I, TA_II, TA_III(a)–(c)), with 3'-alkylthiolated-modified oligonucleotides 
(ALK_DS and ALK_SH) and with their respectively fluorescently labeled versions as well.  
To prepare the conjugates, 5 nmol of desalted oligonucleotide were dissolved in 1 mL of MilliQ water 
and were added to a 1 mL of the gold nanoparticles solution. After 24 h, the solution was brought to a 
final concentration of 10 mM sodium phosphate (pH = 7.2). The mixture was then allowed to 
equilibrate for 30 min before bringing the concentration to 0.15 M NaCl over a 7 h 30 min period in a 
stepwise manner (0.05 M NaCl increments each 2 h 30 min). The solutions were sonicated for 10 s. 
before each addition to keep the particles dispersed during the salting procedure. The salting process 
was followed by an incubation period of 48 h at room temperature. Finally, to remove all unbound 
oligonucleotides, the solution was centrifuged at 13,200 rpm (16,100 ×g) for 30 min. This procedure 
was repeated three times. As we wanted to compare stabilities of the different DNA-AuNP conjugates, 
we dispersed the reddish residue in 500 µL of 0.15 M NaCl, 10 mM sodium phosphate (pH = 7.2), 
0.01% NaN3 solution. Then, each solution was analyzed by UV-visible absorption spectroscopy and 
the concentration of gold nanoparticle conjugates was adjusted to 6.9–7.1 nM by adding the required 
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volume of buffer. The conjugates obtained with the fluorescent oligonucleotides were directly 
resuspended in 1 mL of a 0.15 M NaCl, 10 mM sodium phosphate (pH = 7.2), 0.01% NaN3 solution. 
The extinction coefficient used was the same as that used for unmodified nanoparticles  
(ε520 = 7.6 × 107 M−1·cm−1, data provided by the manufacturer). Each solution was then stored in the 
fridge (4 °C) prior to use. 
3.12. Stability Tests of Oligonucleotide-Gold Nanoparticle Conjugates 
The stability of the different TA-terminated oligonucleotides TA_I, TA_II, TA_III(a)–(c) gold 
nanoparticle conjugates was assessed by treating the AuNP-conjugates with a DTT solution based on 
protocols described in the literature [22,37]. The colloidal stability of AuNP conjugates obtained with 
disulfide and thiol modified oligonucleotides (ALK_DS and ALK_SH respectively) were studied as 
well for comparison purposes. Then, to a 500 µL of each solution were added 12.5 µL of a 4 M DTT 
solution (the final concentration of DTT was 100 mM). Prior to the addition of DTT, the solutions 
were allowed to equilibrate at 40 °C and were sonicated for 20 s to keep the particles dispersed.  
To give an indication of the durability of the oligonucleotide conjugates, absorbance at 675 nm was 
monitored against time at 40 °C. For AuNPs conjugated with TA-terminated oligonucleotides absorbance 
was recorded at 1 min intervals and for AuNPs conjugated with alkylthiolated oligonucleotides absorbance 
was recorded at 1 s intervals. The measures were performed with 0.5 cm quartz cuvettes. The cells 
used had a ground hole at the top to adapt a PTFE stopper to provide a more suitable seal to reduce 
evaporation of the sample. Then, the half-life (time to reach half the value for complete aggregation) 
was calculated for each conjugate by fitting the data obtained to a Boltzmann equation using the Origin 
8.0 software. 
3.13. Oligonucleotide Loading Quantification on Gold Nanoparticles 
The number of oligonucleotides loaded onto gold nanoparticles was analyzed following procedures 
previously described [37,47]. First, the concentration of nanoparticles and the concentration of 
fluorescent DNA in each sample were measured followed by the displacement of fluorescent 
oligonucleotides from the nanoparticle surface using a DTT solution. To this end, 200 µL of the gold 
nanoparticle conjugate solution were treated with 200 µL of a 1 M DTT solution in 0.18 M sodium 
phosphate buffer, (pH = 8) at room temperature for 2 h. The sample was centrifuged to remove the 
sediment from the supernatant and then the fluorescence spectra were recorded (conditions: λEx = 495 nm 
and λEm = 510 − 550 nm). For each oligonucleotide two different oligonucleotide-AuNP conjugates 
were prepared and two different samples were prepared for each conjugate. Fluorescent measurements 
were done in duplicate. Standard curves were prepared with known concentrations of the fluorescently 
labeled TA-terminated oligonucleotide (F)TA_I using the same buffer, salt and DTT concentrations. 
The average number of oligonucleotides per particle was obtained by dividing the measured 
oligonucleotide molar concentration by the original oligonucleotide-AuNP conjugate concentration.  
The average area that each oligonucleotide occupies on the nanoparticle surface (footprint) was calculated 
by dividing the calculated surface area (nm2) by the average number of oligonucleotides per particle. 
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3.14. Stability of Thioctic Derivatives to Cathepsin 
Cathepsin B was dissolved in this buffer: 50 mM NaCl, 10 mM sodium phosphate pH = 6, 1 mM 
EDTA and 30% glycerol and stored at −20 °C until needed. In order to find the optimal conditions for 
the enzymatic reaction, different assays were carried out at different pH, reaction times and also 
changing the proportions of the agents in the reaction. The optimal conditions were as follow: 13.8 µL 
(0.02 unt/µL) of Cathepsin B were added to 200 µL of a solution containing 0.25 OD’s of different 
modified oligonucleotides (TA_I, TA_II, TA_III(a)–(c)) and 5 mM of reduced glutathione.  
The reaction buffer was 100 mM NaCl, 40 mM sodium acetate, 1 mM EDTA and 1% triton-100x,  
pH = 5. The reaction mixture was left at 37 °C, with soft stirring during 12, 24, 48, 72 and 168 h 
respectively. The reaction was quenched by heating the samples at 70 °C during 20 min. The resulting 
products were analyzed by HPLC. Solvent A: 5% ACN in 100 mM TEAA (pH = 7) and solvent B: 
70% ACN in 100 mM TEAA (pH = 7). Column: Nucleosil 120‒10 C18; (250 × 4 mm). Flow rate:  
1 mL/min. Conditions: 20 min of linear gradient from 10% to 40% of B. The isolated products were 
analyzed by mass spectrometry. 
4. Conclusions  
L-Threoninol has been used as a building block to introduce in a covalent way to a DNA sequence 
four different ligands in length containing a TA moiety. All TA-appended oligonucleotide conjugates 
were efficiently loaded on gold nanoparticles. Stability experiments confirmed that all DNA-gold 
nanoparticle conjugates with TA modified at 3'-termini showed better stabilities through thiol 
exchange in the presence of DTT than those conjugates containing acyclic disulfides such as the 
commercially available 3'-thiol modifiers. On the other hand, we observed that oligonucleotides loaded 
onto gold nanoparticles containing a TA-alkyl ligand (AuNP-TA_III(c)) or a TA-oligo(ethylene 
glycol) ligand (AuNP-TA_III(a)) showed a remarkable increase in probe stability probably due to the 
disposal of the spacers, covering and protecting the gold nanoparticle surface. This increase in the stability 
of the system may be also due to the position of the amide group, which may induce favorable interactions 
between the neighboring alkyl or oligo(ethylene glycol) chains. Finally, the thioctic derivative carrying the 
triglycine linker is shown to be the most sensitive to cathepsin B. These preliminary results may open the 
door to an interesting application for these oligonucleotide derivatives in cellular delivery applications.  
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